Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

European Neuropsychopharmacology

Volumn 23, Issue 2, 2013, Pages 118-125

  Soares Weiser, Karla ^a   Béchard Evans, Laura ^a   Howard Lawson, Anthony ^b   Davis, John ^c   Ascher Svanum, Haya ^b  

^a Enhance Reviews Ltd   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antipsychotics; Meta analysis; Schizophrenia; Systematic review

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COMPARATIVE EFFECTIVENESS RESEARCH; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH SUPPORT AS TOPIC; SCHIZOPHRENIA; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 84873523205     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.05.001     Document Type: Article

References (33)

1. Bagnall A.M., Jones L., Ginnelly L., Lewis R., Glanville J., Gilbody S., Davies L., Torgerson D., Kleijnen J. A systematic review of atypical antipsychotic drugs in schizophrenia Health. Technol. Assessment 2003, 7:1-204.
2. Beasley C.M., Stauffer V.L., Liu-Seifert H., Taylor C.C., Dunayevich E., Davis J.M. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis. J. Clin. Psychopharmacol. 2007, 27:252-258.
3. Borenstein M., Hedges L.V., Higgins J.P.T., Rothstein H.R. Introduction to meta-analysis 2009, John Wiley and Sons Ltd., Chichester.
4. Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 2001, 158:518-526.
5. Citrome L., Jaffe A., Martello D., Allingham B., Levine J. Datapoints: did CATIE influence antipsychotic use?. Psychiatr. Serv. 2008, 59:476.
6. Cramer J., Spilker B. Patient compliance in medical practice and clinical trials 1991, Raven Press, New York.
7. Davis J.M., Chen N., Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 2003, 60:553-564.
8. Downs S.H., Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J. Epidemiol. Community Health 1998, 52:377-384.
9. Dunayevich E., Ascher-Svanum H., Zhao F., Jacobson J.G., Phillips G.A., Dellva M.A., Green A.I. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. J. Clin. Psychiatry 2007, 68:1163-1171.
10. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br. Med. J. 2000, 321:1371-1376.
11. Gotzsche P.C., Hrobjartsson A., Johansen H.K., Haahr M.T., Altman D.G., Chan A.W. Constraints on publication rights in industry-initiated clinical trials. J. Am. Med. Assoc. 2006, 295:1645-1646.
12. Haahr M.T., Hrobjartsson A. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors. Clin. Trials 2006, 3:360-365.
13. Heres S., Davis J., Maino K., Jetzinger E., Kissling W., Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am. J. Psychiatry 2006, 163:185-194.
14. Higgins, J.P.T., Green, S. (Eds.), 2008. Cochrane Handbook for Systematic Reviews of Interventions, first ed. John Wiley and Sons Ltd., Chichester.
15. Hodgson R., Bushe C., Hunter R. Measurement of long-term outcomes in observational and randomised controlled trials. Br. J. Psychiatry 2007, 191:s78-s84.
16. Insel T.R. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch. Gen. Psychiatry 2009, 66:128-133.
17. Jayaram M.B., Hosalli P., Stroup S. Risperidone versus olanzapine for schizophrenia, cochrane database of systematic reviews 2006, John Wiley and Sons, Ltd., Chichester, UK.
18. Johnsen E., Jorgensen H.A. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 2008, 8.
19. Juni P., Altman D.G., Egger M. Assessing the quality of controlled clinical trials. Br. Med. J. 2001, 323:42-46.
20. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., Löpez-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rüssler A., Grobbee D.E., Group E.S. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 1085-1097.
21. Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 2009, 14:429-447.
22. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
23. Leucht S., Kissling W., Davis J.M. Second-generation antipsychotics for schizophrenia: can we resolve the conflict?. Psychol. Med. 2009, 1-12.
24. Lewis S.W., Barnes T.R., Davies L., Murray R.M., Dunn G., Hayhurst K.P., Markwick A., Lloyd H., Jones P.B. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr. Bull. 2006, 32:715-723.
25. Lieberman J.A., Scott Stroup T., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S.E., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
26. Liu-Seifert H., Adams D.H., Kinon B.J. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005, 3:21.
27. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 2006, 163:600-610.
28. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl. 1):1-93.
29. Parks J., Radke A., Parker G., Foti M.-E., Eilers R., Diamond M., Svendsen D., Tandon R. Principles of antipsychotic prescribing for policy makers, circa 2008. Translating knowledge to promote individualized treatment. Schizophr. Bull. 2009, 35:931-936.
30. Schulz K.F., Chalmers I., Grimes D.A., Altman D.G. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. J. Am. Med. Assoc. 1994, 272:125-128.
31. Simpson M.M., Goetz R.R., Devlin M.J., Goetz S.A., Walsh B.T. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods. J. Clin. Psychiatry 2001, 62:694-700.
32. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
33. Zarin D.A., Young J.L., West J.C. Challenges to evidence-based medicine: a comparison of patients and treatments in randomized controlled trials with patients and treatments in a practice research network. Soc. Psychiatry Psychiatr. Epidemiol. 2005, 40:27-35.